MiNK's agenT-797 Shows Early Survival Signal in Randomized ARDS Trial
INKT sits 31% above its 52-week low of $8.48 on light trading volume (0.2× avg).
Summary
MiNK reported Q2 results alongside the first clinical observations from its randomized Phase 2 trial of agenT-797 in acute lung injury/ARDS. Initial Day 28 data from ventilated patients in Ukraine showed all treated patients alive and afebrile, with improved oxygenation, ARDS resolution, and no major serious adverse events attributed to the therapy. The company also launched a paid named-patient access program in Brazil, generating early revenue. These are early, uncontrolled observations, but they mark the first randomized validation of the platform in a high-mortality indication with no approved therapies. Additional data are expected in early 2027.
At the time of this announcement, INKT was trading at $11.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $8.48 to $18.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.